Finance

Lists
Why is CVM up ၅.၇၉%?
Dive Deeper
CVM:NYSEAMERICAN
CEL-SCI Corp
၁.၂၈ US$
+၅.၇၉%
(+၀.၀၇၀) 1D
နို ၁၃, GMT-၅ ၁၆:၀၀:၀၀  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CVM...
Open
၁.၁၉ US$
High
၁.၂၈ US$
Low
၁.၁၅ US$
Mkt. cap
၂.၂၅ ကုဋေ
Avg. vol.
၁.၉၈ သိန်း
Volume
၁.၄၆ သိန်း
52-wk high
၇.၈၀ US$
52-wk low
၀.၈၉ US$
EPS
-၂.၆၈ US$
Beta
၀.၆၂
Shares outstanding
၁.၇၆ ကုဋေ
No. of employees
၄၃
Open
၁.၁၉ US$
High
၁.၂၈ US$
Low
၁.၁၅ US$
Mkt. cap
၂.၂၅ ကုဋေ
Avg. vol.
၁.၉၈ သိန်း
Volume
၁.၄၆ သိန်း
52-wk high
၇.၈၀ US$
52-wk low
၀.၈၉ US$
EPS
-၂.၆၈ US$
Beta
၀.၆၂
Shares outstanding
၁.၇၆ ကုဋေ
No. of employees
၄၃
News stories
From web sources and news partners
Foreign Policy Journal
Foreign Policy Journal
·
ပြီးခဲ့သည့် ၇ မိနစ်
Applied Digital (NASDAQ: APLD) Deploys AR Tech To Protect Margins As $6.4B Debt Load Weighs On Expansion Plans
Bloomberg.com
Bloomberg.com
·
ပြီးခဲ့သည့် ၂ နာရီ
Asian Stocks Brace for AI Pressure, Data Dump: Markets Wrap
Investor's Business Daily
Investor's Business Daily
·
ပြီးခဲ့သည့် ၂ နာရီ
Dow Jones Futures Due; How Will Nvidia React As Jensen Huang Mulls Return?
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees၄၃
Foundedမတ် ၁၉၈၃
Headquartersဗီယင်နာ, ဗာဂျီးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth Care
Industry-
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
-
-
-
-
Cost of goods sold
၃.၇၀ သန်း
၃.၆၈ သန်း
၃.၇၇ သန်း
၃.၆၅ သန်း
Cost of revenue
၃.၇၀ သန်း
၃.၆၈ သန်း
၃.၇၇ သန်း
၃.၆၅ သန်း
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၂.၃၃ သန်း
၁.၆၉ သန်း
၁.၅၆ သန်း
၁.၉၁ သန်း
Operating expense
၂.၃၃ သန်း
၁.၆၉ သန်း
၁.၅၆ သန်း
၁.၉၁ သန်း
Total operating expenses
၆.၀၃ သန်း
၅.၃၇ သန်း
၅.၃၃ သန်း
၅.၅၆ သန်း
Operating income
-၆.၀၃ သန်း
-၅.၃၇ သန်း
-၅.၃၃ သန်း
-၅.၅၆ သန်း
Other non operating income
၆.၀၉ သောင်း
-
-၂.၂၃ သောင်း
-
EBT including unusual items
-၆.၁၀ သန်း
-၅.၄၇ သန်း
-၅.၄၇ သန်း
-၅.၆၇ သန်း
EBT excluding unusual items
-၆.၁၀ သန်း
-၅.၄၆ သန်း
-၅.၄၇ သန်း
-၅.၆၇ သန်း
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၆.၁၀ သန်း
-၅.၄၇ သန်း
-၅.၄၇ သန်း
-၅.၆၇ သန်း
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-၁.၂၉ သိန်း
-၈.၇၈ သောင်း
-၁.၁၇ သိန်း
-၁.၁၀ သိန်း
Net interest expenses
-၁.၂၉ သိန်း
-၈.၇၈ သောင်း
-၁.၁၇ သိန်း
-၁.၁၀ သိန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၅.၅၁ သန်း
-၄.၄၀ သန်း
-၄.၃၇ သန်း
-၄.၆၁ သန်း
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ